Reuters · Nov 2025
Reuters reported that Red Queen Bio was spun out of HelixNano and that OpenAI led a $15 million seed round in the new biosecurity company co-founded by Hannu Rajaniemi.
Next-generation mRNA platform to solve cancer, COVID and climate.
Company research
Public company, workplace, funding, and market signals
Overview
Helix Nanotechnologies (HelixNano) is a 2013-founded biotech focused on an mRNA platform for vaccines and therapeutics. Public materials describe a first-principles, AI/synthetic-biology-driven approach aimed at improving mRNA potency, breadth, manufacturability, and immune-system targeting, with HN-0001 as its leading next-generation COVID-19 vaccine candidate.
Primary product
mRNA platform and HN-0001 next-generation COVID-19 vaccine candidate
Founded
2013
Headquarters
Cambridge, Massachusetts, United States
Team size
10-20
Industry
Biotechnology Research
Sub-industry
mRNA therapeutics / vaccine platform
Offices
5 Channel Center Street, Suite 600, Boston, MA 02210
Cambridge, Massachusetts, United States
Business model
biotech R&D platform
drug development
clinical-stage therapeutics
pharma/biotech partnerships
Funding
Stage
Series A
Total raised
$59.2M
Latest round
Unattributed VC · May 2024
People & investors
Leadership
Co-Founder and CEO
Co-Founder and CSO
Chief Scientific Officer
Director, CMC Strategy
Founders
Co-Founder, Board Member and former CEO
Investors
Altman Family, LLC
Alumni Ventures
BakerBridge Capital
Breakthrough Energy
BZH Capital Partners
Champion Hill Ventures
DCVC
Dhuna Ventures
Foobar Technologies
Hopper-Dean Investors
Lifeline Ventures
Marstar Alternative Investments
Milano Investment Partners SGR
Odesangel AB
Schmidt Futures
Starlight Ventures
Synthetic Biology Grant Program
Vorago Holdings Oy
Y Combinator
Yes VC
Work & culture
Mission-driven, high-agency, flat-hierarchy culture that emphasizes empowering individual scientists, curiosity-driven experimentation, cross-disciplinary work, and coaching/mentoring.
Compensation
No public salary bands were found. The clearest compensation signal is a Boston RA posting that offers relocation assistance, but no pay range was disclosed.
Benefits
Relocation assistance (lump sum) for the Boston RA role
Product & market
Pricing
Not publicly disclosed; appears to rely on R&D platform collaborations and clinical-development partnerships.
Differentiators
- —First-principles mRNA optimization
- —AI + synthetic biology orientation
- —Claims broader and more mutation-resistant immune responses
- —Platform intended across multiple indications beyond COVID
- —Small-team, high-agency operating model
- —Potential thermostable / alternative-delivery collaborations
Technology
mRNA
mRNA-LNP
lipid nanoparticles (LNPs)
AI-assisted design
synthetic biology
gene delivery
PCR
capillary assays
AMP
microfluidic synthesis
dynamic light scattering (DLS)
UV/vis spectroscopy
GMP manufacturing
Competitors
Moderna
BioNTech
CureVac
Novavax
Pfizer/BioNTech
Scale & contact
Estimated revenue
≈$1M–$25M (third-party estimates vary widely; no audited public revenue)
Estimated monthly visits
891
Traffic estimate as of Jul 2026
Latest news
Medicus Pharma / Newsfile · Aug 2025
HelixNano signed a non-binding MOU with Medicus Pharma to combine HelixNano's mRNA vaccine platform with Medicus' microneedle-array delivery platform for thermostable infectious-disease vaccines, including HN-0001.
Sifted · Apr 2024
Profile/interview on cofounder Carina Namih discussing HelixNano's origin, culture, fundraising, and the company's move into human-stage clinical trials.
EINPresswire · Mar 2024
HelixNano Australia received ethics approval to begin Phase 1 testing of HN-0001, a next-generation COVID-19 mRNA vaccine candidate intended for immunosuppressed and immunocompromised populations.
Medium · Feb 2019
HelixNano announced a Schmidt Futures grant to support machine-learning-enabled personalized cancer vaccine work with collaborators at the Broad Institute and Parker Institute.
Jobs and careers at Helix Nanotechnologies
0 jobs at Helix Nanotechnologies
No open positions
Check back later for new openings